Tarsus Pharmaceuticals, Inc. (TARS)

Key Insights

• The reporting person, Katherine Goodrich, exercised 2,233 restricted stock units (RSUs) on 12/15/2025, indicating their continued ownership and vesting of company equity.
• The RSUs have a 3-year vesting schedule, with additional tranches vesting in 2026 and 2027, aligning the reporting person's incentives with long-term company performance.
• The reporting person's direct ownership of Tarsus Pharmaceuticals, Inc. (TARS) shares increased to 2,233 following the RSU exercise, suggesting they maintain a meaningful stake in the company.